|
|
News Breaks | | | | December 9, 2012 | | 13:55 EDT |  | ARIA | ARIAD announces 12-month data from PACE trial of ponatinib
ARIAD Pharmaceuticals announced twelve-month follow-up data from the pivotal PACE trial of ponatinib, its investigational BCR-ABL inhibitor, in heavily pretreated patients with resistant or refractory chronic myeloid leukemia, CML, or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study now shows that 56 percent of chronic-phase CML patients in the trial, including 70 percent of patients with a T315I mutation, achieved a major cytogenetic response (MCyR), the primary end-point for chronic-phase CML patients. The data are being featured today at 4:30 p.m., ET, in an oral presentation at the 54th Annual Meeting of the American Society of Hematology, ASH, being held in Atlanta, Georgia. ARIAD filed for regulatory approval of ponatinib in the third quarter of 2012 in the U.S. and in the E.U. based on clinical data from the pivotal PACE trial. | |
|
News For ARIA From The Last 14 Days Check below for free stories on ARIA the last two weeks. |
|
|
| June 11, 2013 | | 07:41 EDT | | ARIA | ARIAD initiates Phase 2 trial of Iclusig
 Subscribe for More Information | | | 07:27 EDT |  | ARIA | William Blair to host a conference
Subscribe for More Information | | | June 7, 2013 | | 08:17 EDT | | ARIA | ARIAD has a conference call hosted by JPMorgan
Subscribe for More Information | |
|
|
|
|
|
|
